A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their strict tumoral specificity and because they are shared by many tumors. Antigenic peptide EVDPIGHLY encoded by MAGE-3 and known to be presented by HLA-A*0101 is currently being used in therapeutic vaccination trials. We report here that a cytolytic T-lymphocyte (CTL) clone, which is restricted by HLA-B*3501, recognizes the same peptide and, importantly, lyses HLA-B*3501 tumor cells expressing MAGE-3. These results infer that the current clinical use of peptide EVDPIGHLY can now be extended to HLA-B*3501 patients.
Ludwig Institute for Cancer Research, Brussels, Belgium.
E S
ES
Schultz
Y
Y
Zhang
R
R
Knowles
J
J
Tine
C
C
Traversari
T
T
Boon
P
P
van der Bruggen
D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D015870:Gene Expression / Q000276:immunology; D015788:HLA-A1 Antigen / Q000276:immunology*; D015797:HLA-B35 Antigen / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D008545:Melanoma; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D000939:Epitopes; D015788:HLA-A1 Antigen; D015797:HLA-B35 Antigen; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D007371:Interferon-gamma